Junshi Biosciences News and Activities
Presence
Junshi Biosciences develops and sells biopharmaceutical medicines. Its main products include cancer, autoimmune, and infectious disease treatments for hospitals, healthcare providers, and patients.
Junshi Biosciences products and services overview:
- Cancer treatments
- Autoimmune therapies
- Infectious disease drugs
- Biologic medicines
- Drug discovery services
Revenue: ~$270 million
Employees: 2,500
Headquarters: Shanghai, China
Junshi Biosciences is one of the...
Junshi Biosciences is a company listed under the stock ticker 688180 (HK).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Junshi Biosciences
- Jianjun Zou, Managing Director and Chief Executive Officer
- Tang Yi, Non-Executive Director
- Lu Kun, Independent Non-executive Directors
Create your alert
to follow the executive moves at Junshi Biosciences.
Biotechnology
Junshi Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Junshi Biosciences
Social media about Junshi Biosciences
- Junshi Biosciences on Wikipedia, Google News & Yahoo Finance
- Junshi Biosciences on LinkedIn, X (Twitter) & YouTube
